TAFRO综合征肾脏表现的临床与组织病理学特征
本研究为病例系列,评估7例TAFRO综合征患者的肾脏组织学。所有患者均有严重利尿剂抵抗性全身水肿,6/7有轻度蛋白尿(<1 g/日)。光镜下均见肾小球内皮病,表现为内皮细胞肿胀、肾小球基底膜双轨征伴系膜溶解或系膜疏松;免疫荧光和电镜未检出免疫沉积物。糖皮质激素及分子靶向治疗(托珠单抗、利妥昔单抗)改善肾功能和水肿。
要点
- TAFRO综合征肾损害特征为严重利尿剂抵抗性水肿伴轻度蛋白尿。
- 肾活检光镜示肾小球内皮病,无免疫沉积物。
- 糖皮质激素及IL-6/VEGF靶向治疗可改善肾功能和水肿。
核心结论
- 严重利尿剂抵抗性全身水肿伴轻度蛋白尿和严重肾小球内皮病是TAFRO综合征肾损害的常见特征。
- IL-6和VEGF介导的内皮改变导致血管高通透性和水分渗漏,可能参与全身水肿发生,因针对IL-6或VEGF的分子靶向治疗改善了肾功能和严重内皮损伤。
研究设计与样本
- 病例系列研究,评估在本院治疗的TAFRO综合征患者的肾脏组织学,7例患者符合纳入标准。
主要发现
- 所有7例患者均有严重利尿剂抵抗性全身水肿,6/7有轻度蛋白尿(<1 g/日)。
- 光镜下所有患者均显示肾小球内皮病,特征为内皮细胞肿胀和肾小球基底膜双轨征伴系膜溶解或系膜疏松。
- 免疫荧光染色和电镜未在任何患者中检出免疫沉积物。
- 电镜显示内皮细胞肿胀伴内皮下间隙弥漫性扩张、系膜结构丧失和内皮细胞窗孔丧失。
- 糖皮质激素和分子靶向药物(包括托珠单抗和利妥昔单抗)治疗改善了肾功能和全身水肿;7例中4例持续血小板减少患者尽管接受血小板输注或血小板生成素受体激动剂治疗仍发生出血事件。
临床怎么用
- 对TAFRO综合征相关肾损害,可考虑糖皮质激素联合IL-6或VEGF靶向治疗以改善肾功能和水肿。
- 肾活检见肾小球内皮病且无免疫沉积物有助于支持TAFRO综合征肾损害的诊断。
局限性
- 本研究为单中心病例系列,样本量小(7例),未设对照,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman's disease, characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, and organomegaly. Renal complication of this disease can be life-threatening and sometimes requires hemodialysis, but it has not been elucidated in detail. METHODS: Case-series was designed to evaluate the renal histology of patients with TAFRO syndrome treated at our hospital. RESULTS: Seven patients were eligible to the criteria. All of them had severe diuretic-resistant anasarca and 6 of 7 had mild proteinuria (<1 g daily). On light microscopy, all patients showed glomerular endotheliopathy characterized by endothelial cell swelling and a double contour of the glomerular basement membrane with mesangiolysis or mesangial loosening. Immunofluorescent staining and electron microscopy did not detect immune deposits in any patient. Electron microscopy revealed endothelial cell swelling with diffuse expansion of the subendothelial space, loss of mesangial architecture, and loss of endothelial cell fenestrations. Treatment with glucocorticoids and molecular-targeting agents, including tocilizumab and rituximab, improved renal dysfunction and anasarca. In 4 of 7 patients with persistent thrombocytopenia, hemorrhagic events occurred despite platelet transfusion or thrombopoietin receptor antagonist therapy. CONCLUSION: Severe diuretic-resistant anasarca with mild proteinuria and severe glomerular endotheliopathy were common characteristics of renal dysfunction due to TAFRO syndrome. In addition, endothelial changes mediated via interleukin (IL)-6 and vascular endothelial growth factor (VEGF) that lead to vascular hyperpermeability and water leakage might contribute to anasarca, because molecular-targeting therapy directed against IL-6 or VEGF improved renal dysfunction and severe endothelial damage.
引用
- Mizuno H, Sawa N, Watanabe S, et al. The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome. Kidney Int Rep. 2020. PMID: 32775816. doi:10.1016/j.ekir.2020.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。